Investors
Corporate Profile
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic and autologous CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.
NASDAQ
EURONEXT
Stock Information
Financial Market Data powered by Quotemedia. All rights reserved.
View the Terms of Use. Data delayed 15 minutes unless indicated.
ISIN: BE0974260896-XBRU Updated at
Financial Calendar
March 24, 2021
FY 2020 Financial Results
May 6, 2021
Q1 2021 Financial Results
August 4, 2021
H1 2021 Financial Results
Nov 10, 2021
Q3 2021 Financial Results
Investors Kit
Corporate Presentation
Corporate Fact Sheet
Annual Report 2020
Upcoming Events
10
Nov
2021
Third Quarter 2021 Financial Results and Recent Business Highlights
12
Nov
2021
SITC 2021 Annual Meeting
